| 2026-05-26 |
详情>>
内部人交易：
Campbell Shannon股份增加114200.00股
|
| 2026-05-12 |
详情>>
业绩披露：
2026年一季报每股收益-0.5美元,归母净利润-3535.2万美元,同比去年增长26.78%
|
| 2026-04-30 |
股东大会：
将于2026-06-16召开股东大会
会议内容 ▼▲
- 1.To elect David Johnson and Jan Skvarka, Ph.D. as Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2026-04-30 |
详情>>
股本变动：
变动后总股本7118.63万股
|
| 2026-03-26 |
详情>>
业绩披露：
2025年年报每股收益-1.91美元,归母净利润-1.37亿美元,同比去年增长17.35%
|
| 2026-03-26 |
详情>>
业绩披露：
2023年年报每股收益-4.47美元,归母净利润-2.92亿美元,同比去年增长-23.39%
|
| 2026-01-12 |
复牌提示：
2026-01-12 09:35:35 停牌，复牌日期 2026-01-12 09:40:35
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.42美元,归母净利润-1.02亿美元,同比去年增长13.96%
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-1.05美元,归母净利润-7515.3万美元,同比去年增长3.91%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.67美元,归母净利润-4827.9万美元,同比去年增长-579.53%
|
| 2025-04-30 |
股东大会：
将于2025-06-17召开股东大会
会议内容 ▼▲
- 1.To elect Scott Myers, Karan Takhar and Luke Walker, M.D., as Class II directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2025-03-26 |
详情>>
业绩披露：
2024年年报每股收益-2.33美元,归母净利润-1.66亿美元,同比去年增长43.24%
|
| 2025-03-26 |
详情>>
业绩披露：
2022年年报每股收益-4.48美元,归母净利润-2.37亿美元,同比去年增长-49.19%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.67美元,归母净利润-1.18亿美元,同比去年增长48.82%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-1.1美元,归母净利润-7820.9万美元,同比去年增长55.50%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益0.14美元,归母净利润1006.80万美元,同比去年增长115.93%
|
| 2024-04-29 |
股东大会：
将于2024-06-21召开股东大会
会议内容 ▼▲
- 1.To elect Kimberly Blackwell, M.D., and Enoch Kariuki, Pharm.D., as Class I directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
4.To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2023-04-28 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect David Johnson and Jan Skvarka, Ph.D., as Class III directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve an amendment to our Certificate of Incorporation to update the exculpation provision with respect to certain officers of the Company as permitted by recent amendments to the General Corporation Law of the State of Delaware;
4.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers;
5.To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2022-04-28 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect Cam S. Gallagher and Karan S. Takhar as Class II Directors to serve until the 2025 Annual Meeting of Stockholders, and until their respective successors shall have been duly-elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers (“Say-on-Pay Vote”);
4.To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-04召开股东大会
会议内容 ▼▲
- 1.To elect Kimberly Blackwell, M.D. and Enoch Kariuki, Pharm.D. as Class I Directors to serve until the 2024 Annual Meeting of Stockholders, and until their respective successors shall have been duly-elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve the amendment and restatement of the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|